Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 1
1995 1
1996 1
1998 2
1999 1
2000 3
2001 6
2002 4
2003 6
2004 8
2005 6
2006 7
2007 8
2008 9
2009 10
2010 22
2011 20
2012 18
2013 18
2014 9
2015 5
2016 8
2017 12
2018 9
2019 10
2020 13
2021 9
2022 10
2023 10
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

223 results

Results by year

Filters applied: . Clear all
Page 1
Proposal for a Biologic Staging System of Parkinson's Disease.
Chahine LM, Merchant K, Siderowf A, Sherer T, Tanner C, Marek K, Simuni T. Chahine LM, et al. Among authors: siderowf a. J Parkinsons Dis. 2023;13(3):297-309. doi: 10.3233/JPD-225111. J Parkinsons Dis. 2023. PMID: 37066922 Free PMC article. Review.
Assessment of heterogeneity among participants in the Parkinson's Progression Markers Initiative cohort using α-synuclein seed amplification: a cross-sectional study.
Siderowf A, Concha-Marambio L, Lafontant DE, Farris CM, Ma Y, Urenia PA, Nguyen H, Alcalay RN, Chahine LM, Foroud T, Galasko D, Kieburtz K, Merchant K, Mollenhauer B, Poston KL, Seibyl J, Simuni T, Tanner CM, Weintraub D, Videnovic A, Choi SH, Kurth R, Caspell-Garcia C, Coffey CS, Frasier M, Oliveira LMA, Hutten SJ, Sherer T, Marek K, Soto C; Parkinson's Progression Markers Initiative. Siderowf A, et al. Lancet Neurol. 2023 May;22(5):407-417. doi: 10.1016/S1474-4422(23)00109-6. Lancet Neurol. 2023. PMID: 37059509 Free PMC article.
Trial of Cinpanemab in Early Parkinson's Disease.
Lang AE, Siderowf AD, Macklin EA, Poewe W, Brooks DJ, Fernandez HH, Rascol O, Giladi N, Stocchi F, Tanner CM, Postuma RB, Simon DK, Tolosa E, Mollenhauer B, Cedarbaum JM, Fraser K, Xiao J, Evans KC, Graham DL, Sapir I, Inra J, Hutchison RM, Yang M, Fox T, Budd Haeberlein S, Dam T; SPARK Investigators. Lang AE, et al. Among authors: siderowf ad. N Engl J Med. 2022 Aug 4;387(5):408-420. doi: 10.1056/NEJMoa2203395. N Engl J Med. 2022. PMID: 35921450 Clinical Trial.
A biological definition of neuronal α-synuclein disease: towards an integrated staging system for research.
Simuni T, Chahine LM, Poston K, Brumm M, Buracchio T, Campbell M, Chowdhury S, Coffey C, Concha-Marambio L, Dam T, DiBiaso P, Foroud T, Frasier M, Gochanour C, Jennings D, Kieburtz K, Kopil CM, Merchant K, Mollenhauer B, Montine T, Nudelman K, Pagano G, Seibyl J, Sherer T, Singleton A, Stephenson D, Stern M, Soto C, Tanner CM, Tolosa E, Weintraub D, Xiao Y, Siderowf A, Dunn B, Marek K. Simuni T, et al. Among authors: siderowf a. Lancet Neurol. 2024 Feb;23(2):178-190. doi: 10.1016/S1474-4422(23)00405-2. Lancet Neurol. 2024. PMID: 38267190 Review.
Preclinical and clinical evaluation of the LRRK2 inhibitor DNL201 for Parkinson's disease.
Jennings D, Huntwork-Rodriguez S, Henry AG, Sasaki JC, Meisner R, Diaz D, Solanoy H, Wang X, Negrou E, Bondar VV, Ghosh R, Maloney MT, Propson NE, Zhu Y, Maciuca RD, Harris L, Kay A, LeWitt P, King TA, Kern D, Ellenbogen A, Goodman I, Siderowf A, Aldred J, Omidvar O, Masoud ST, Davis SS, Arguello A, Estrada AA, de Vicente J, Sweeney ZK, Astarita G, Borin MT, Wong BK, Wong H, Nguyen H, Scearce-Levie K, Ho C, Troyer MD. Jennings D, et al. Among authors: siderowf a. Sci Transl Med. 2022 Jun 8;14(648):eabj2658. doi: 10.1126/scitranslmed.abj2658. Epub 2022 Jun 8. Sci Transl Med. 2022. PMID: 35675433
Neurofilament Light Chain as a Biomarker for Cognitive Decline in Parkinson Disease.
Aamodt WW, Waligorska T, Shen J, Tropea TF, Siderowf A, Weintraub D, Grossman M, Irwin D, Wolk DA, Xie SX, Trojanowski JQ, Shaw LM, Chen-Plotkin AS. Aamodt WW, et al. Among authors: siderowf a. Mov Disord. 2021 Dec;36(12):2945-2950. doi: 10.1002/mds.28779. Epub 2021 Sep 4. Mov Disord. 2021. PMID: 34480363 Free PMC article.
Parkinson's Progression Markers Initiative: A Milestone-Based Strategy to Monitor Parkinson's Disease Progression.
Brumm MC, Siderowf A, Simuni T, Burghardt E, Choi SH, Caspell-Garcia C, Chahine LM, Mollenhauer B, Foroud T, Galasko D, Merchant K, Arnedo V, Hutten SJ, O'Grady AN, Poston KL, Tanner CM, Weintraub D, Kieburtz K, Marek K, Coffey CS; Parkinson’s Progression Markers Initiative. Brumm MC, et al. Among authors: siderowf a. J Parkinsons Dis. 2023;13(6):899-916. doi: 10.3233/JPD-223433. J Parkinsons Dis. 2023. PMID: 37458046 Free PMC article.
Author response.
Weintraub D, Siderowf A, Papay K. Weintraub D, et al. Among authors: siderowf a. Neurology. 2013 Aug 13;81(7):694-5. Neurology. 2013. PMID: 24137626 No abstract available.
Screening questionnaires for parkinsonism: a systematic review.
Dahodwala N, Siderowf A, Baumgarten M, Abrams A, Karlawish J. Dahodwala N, et al. Among authors: siderowf a. Parkinsonism Relat Disord. 2012 Mar;18(3):216-24. doi: 10.1016/j.parkreldis.2011.09.003. Epub 2011 Sep 17. Parkinsonism Relat Disord. 2012. PMID: 21930414 Free PMC article. Review.
223 results